AEterna Zentaris (AEterna Zentaris) Days Payable : 4,285.43 (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is AEterna Zentaris Days Payable?

AEterna Zentaris's average Accounts Payable for the three months ended in Dec. 2023 was $2.58 Mil. AEterna Zentaris's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.06 Mil. Hence, AEterna Zentaris's Days Payable for the three months ended in Dec. 2023 was 4,285.43.

The historical rank and industry rank for AEterna Zentaris's Days Payable or its related term are showing as below:

AEZS' s Days Payable Range Over the Past 10 Years
Min: 181.45 Med: 2147.13 Max: 4948.76
Current: 4948.76

During the past 13 years, AEterna Zentaris's highest Days Payable was 4948.76. The lowest was 181.45. And the median was 2147.13.

AEZS's Days Payable is ranked better than
93.42% of 714 companies
in the Biotechnology industry
Industry Median: 147.95 vs AEZS: 4948.76

AEterna Zentaris's Days Payable increased from Dec. 2022 (2,467.33) to Dec. 2023 (4,285.43). It may suggest that AEterna Zentaris delayed paying its suppliers.

AEterna Zentaris Days Payable Historical Data

The historical data trend for AEterna Zentaris's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Days Payable Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

1,054.49

179.11

4,300.92

3,454.71

3,209.37

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															2,467.33	16,553.82	2,528.08	28,503.18	4,285.43

Competitive Comparison of AEterna Zentaris's Days Payable

For the Biotechnology subindustry, AEterna Zentaris's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEterna Zentaris's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Days Payable distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Days Payable falls into.

AEterna Zentaris Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

AEterna Zentaris's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (2.038	+	1.866)	/	2 )	/	0.222	*	365
=	1.952					/	0.222	*	365
=	3,209.37

AEterna Zentaris's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (3.3	+	1.866)	/	2 )	/	0.055	*	365 / 4
=	2.583					/	0.055	*	365 / 4
=	4,285.43

AEterna Zentaris Days Payable Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (AEterna Zentaris) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

ET8:Germany ET8:Germany AEZS:Canada

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.